Shruti Bhandari1, Phuong Ngo2, Blakely Kute2, Mounika Mandadi2, Whitney A Pitman3, Xiaoyong Wu4, Sandy Lloyd3, Marie Corliss Brown5, Shesh N Rai4,6, Dharamvir Jain2, Elizabeth C Riley2. 1. Division of Hematology and Medical Oncology, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, 529 S Jackson St, Louisville, KY, 40202, USA. s0bhan04@louisville.edu. 2. Division of Hematology and Medical Oncology, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, 529 S Jackson St, Louisville, KY, 40202, USA. 3. James Graham Brown Cancer Center, University of Louisville, 529 S Jackson St, Louisville, KY, 40202, USA. 4. Biostatistics and Bioinformatics Facility, James Graham Brown Cancer Center, University of Louisville, 505 S Hancock St, Louisville, KY, 40202, USA. 5. Cancer Registry, James Graham Brown Cancer Center, University of Louisville, 550 S Jackson St, Louisville, KY, 40202, USA. 6. Department of Bioinformatics and Biostatistics, School of Public Health and Information Sciences, University of Louisville, 485 E Gray St, Louisville, KY, 40202, USA.
Abstract
PURPOSE: This pilot study evaluated adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging. METHODS: This was a single-arm prospective investigational pilot study that enrolled 86 patients between August 2012 and April 2014. Descriptive statistics for patient age, race, insurance, stage, duration of treatment, and comorbidities were computed. All patients received routine prescriptions in a "bubble" pack or daily blister pack dispensed by one pharmacy. Participants were considered adherent if they had taken ≥ 80% of the dispensed drug. Disease-free survival (DFS) and overall survival (OS) data were obtained at 78 months. RESULTS: Fifty patients were included in the analysis. The overall adherence rate was 97%. None of the variables examined (race, age, insurance status, and stage) had an impact on adherence rate. Only duration of endocrine therapy had a marginal effect on adherence (p value = 0.06). The late cohort (duration of therapy 37-60 months) was least likely to be compliant at 89.53%. Our 5-year DFS was 94% and 5-year OS was 96%. There was no statistically significant difference in DFS and OS between patients with adherence rate > 90% and < 90%. CONCLUSION: Adherence rate to bubble packaging was higher than that in historical studies. Although this is a single-arm pilot study, these data suggest bubble packaging of anti-estrogen may be a reasonable option to improve adherence in hormone receptor-positive breast cancer patients.
PURPOSE: This pilot study evaluated adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging. METHODS: This was a single-arm prospective investigational pilot study that enrolled 86 patients between August 2012 and April 2014. Descriptive statistics for patient age, race, insurance, stage, duration of treatment, and comorbidities were computed. All patients received routine prescriptions in a "bubble" pack or daily blister pack dispensed by one pharmacy. Participants were considered adherent if they had taken ≥ 80% of the dispensed drug. Disease-free survival (DFS) and overall survival (OS) data were obtained at 78 months. RESULTS: Fifty patients were included in the analysis. The overall adherence rate was 97%. None of the variables examined (race, age, insurance status, and stage) had an impact on adherence rate. Only duration of endocrine therapy had a marginal effect on adherence (p value = 0.06). The late cohort (duration of therapy 37-60 months) was least likely to be compliant at 89.53%. Our 5-year DFS was 94% and 5-year OS was 96%. There was no statistically significant difference in DFS and OS between patients with adherence rate > 90% and < 90%. CONCLUSION: Adherence rate to bubble packaging was higher than that in historical studies. Although this is a single-arm pilot study, these data suggest bubble packaging of anti-estrogen may be a reasonable option to improve adherence in hormone receptor-positive breast cancerpatients.
Entities:
Keywords:
Adherence; Anti-estrogen therapy; Breast cancer; Bubble packaging
Authors: Ilana Graetz; Caitlin N McKillop; Edward Stepanski; Gregory A Vidal; Janeane N Anderson; Lee S Schwartzberg Journal: J Cancer Surviv Date: 2018-02-28 Impact factor: 4.442
Authors: Vicki S Conn; Todd M Ruppar; Keith C Chan; Jacqueline Dunbar-Jacob; Ginette A Pepper; Sabina De Geest Journal: Curr Med Res Opin Date: 2014-11-04 Impact factor: 2.580
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2014-04-28 Impact factor: 13.506
Authors: Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman Journal: Breast Cancer Res Treat Date: 2006-03-16 Impact factor: 4.872
Authors: Sue P Heiney; Pearman D Parker; Tisha M Felder; Swann Arp Adams; Omonefe O Omofuma; Jennifer M Hulett Journal: Breast Cancer Res Treat Date: 2018-11-01 Impact factor: 4.872
Authors: C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto Journal: Lancet Date: 2011-07-28 Impact factor: 79.321
Authors: Sophie M C Green; David P French; Christopher D Graham; Louise H Hall; Nikki Rousseau; Robbie Foy; Jane Clark; Catherine Parbutt; Erin Raine; Benjamin Gardner; Galina Velikova; Sally J L Moore; Jacqueline Buxton; Samuel G Smith Journal: BMC Health Serv Res Date: 2022-08-24 Impact factor: 2.908